Biological response genes after single dose administration of interferon beta-1b to healthy male volunteers

Treatment with interferon beta-1b (IFNB-1b) is clinically effective in multiple sclerosis patients. However, the mechanism of action is only partially understood, and validated biological response markers are lacking. We assessed IFNB-1b-induced transcriptional changes by microarray technology. Heal...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuroimmunology 2008-08, Vol.199 (1-2), p.115-125
Main Authors: Hilpert, Jan, Beekman, Johanna M, Schwenke, Susanne, Kowal, Kristin, Bauer, David, Lampe, Johannes, Sandbrink, Rupert, Heubach, Jürgen F, Stürzebecher, Steffen, Reischl, Joachim
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic - pharmacology
Adult
Double-Blind Method
Gene Expression - drug effects
Gene Expression Profiling
Humans
Immunologic Factors - genetics
Interferon beta-1b
Interferon-beta - pharmacology
Male
Oligonucleotide Array Sequence Analysis
Principal Component Analysis
Reverse Transcriptase Polymerase Chain Reaction
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Treatment with interferon beta-1b (IFNB-1b) is clinically effective in multiple sclerosis patients. However, the mechanism of action is only partially understood, and validated biological response markers are lacking. We assessed IFNB-1b-induced transcriptional changes by microarray technology. Healthy male volunteers received 250 mug IFNB-1b or placebo in a double-blind, randomized controlled trial (n=5 per group). Most transcripts demonstrated peak levels after 6-12 h and returned to baseline after 48 h. We identified 227 differentially regulated genes including novel and previously described markers. This panel may become a valuable tool for development of new IFNB-1b formulations and assessment of clinical drug effects.
ISSN:0165-5728
DOI:10.1016/j.jneuroim.2008.04.036